product name Sotagliflozin (LX4211)
Description: Sotagliflozin (also known as LX4211) is an orally bioavailable, dual SGLT1/SGLT2 inhibitor with IC50 of 36 nM and 1.8 nM, respectively. Sotagliflozin improves glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Sotagliflozin also increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose.
References: J Pharmacol Exp Ther. 2013 May;345(2):250-9; Diabetes Metab Syndr Obes. 2015 Feb 26;8:121-7.
424.94
Formula
C21H25ClO5S
CAS No.
1018899-04-1
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 84 mg/mL (197.7 mM)
Water: <1 mg/mL
Ethanol: 17 mg/mL (40.0 mM)
Solubility (In vivo)
Synonyms
LX4211
other peoduct :
| In Vitro |
In vitro activity: LX4211 inhibits [14C]AMG uptake with IC50 of 62.0 nM for mouse SGLT1 and 0.6 nM for mouse SGLT2, respectively. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | In mice, LX4211 (60 mg/kg, p.o.) reduces intestinal glucose absorption by inhibiting SGLT1, resulting in net increases in GLP-1 and PYY release and decreases in GIP release and blood glucose excursions. In nonobese diabetes-prone mice with type 1 diabetes, Sotagliflozin (30 mg/kg) significantly improves glycemic control, without increasing the rate of hypoglycemia measurements. |
| Animal model | Male albino C57BL/6-Tyrc-Brd mice |
| Formulation & Dosage | Dissolved in aqueous 0.1% v/v Tween 80; 60 mg/kg; oral administration. |
| References | J Pharmacol Exp Ther. 2013 May;345(2):250-9; Diabetes Metab Syndr Obes. 2015 Feb 26;8:121-7. |
